{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:52:32Z","timestamp":1789606352158,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11883-021-00919-2","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T04:05:16Z","timestamp":1617163516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-9589","authenticated-orcid":false,"given":"Fabien","family":"Picard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"919_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD","year":"2015","unstructured":"GBD. 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117\u201371.","journal-title":"Lancet"},{"key":"919_CR2","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","volume":"37","author":"N Townsend","year":"2016","unstructured":"Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37:3232\u201345.","journal-title":"Eur Heart J"},{"key":"919_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.tcm.2017.03.004","volume":"27","author":"P Wiesner","year":"2017","unstructured":"\u2022 Wiesner P, Watson KE. Triglycerides: a reappraisal. Trends Cardiovasc Med. 2017;27:428\u201332 Recent comprehensive review on triglycerides.","journal-title":"Trends Cardiovasc Med"},{"key":"919_CR4","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJM199304293281702","volume":"328","author":"MH Criqui","year":"1993","unstructured":"Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med Massachusetts Med Soc. 1993;328:1220\u20135.","journal-title":"N Engl J Med"},{"key":"919_CR5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","volume":"36","author":"P Libby","year":"2015","unstructured":"Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J. 2015;36:774\u20136.","journal-title":"Eur Heart J"},{"key":"919_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","volume":"51","author":"M Miller","year":"2008","unstructured":"Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"919_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","volume":"104","author":"O Faergeman","year":"2009","unstructured":"Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, Kastelein JJP, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104:459\u201363.","journal-title":"Am J Cardiol"},{"key":"919_CR8","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","volume":"65","author":"GG Schwartz","year":"2015","unstructured":"Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65:2267\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"919_CR9","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, et al. Triglyceride coronary disease genetics consortium and emerging risk factors collaboration: Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634\u20139.","journal-title":"Lancet."},{"key":"919_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"919_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","volume":"36","author":"MV Holmes","year":"2015","unstructured":"Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J. 2015;36:539\u201350.","journal-title":"Eur Heart J"},{"issue":"1","key":"919_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2018","unstructured":"\u2022\u2022 Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018;380(1):11\u201322 NEJMoa1812792. Major trial demonstrating CVD risk reduction (composite primary outcome of cardiovascular death, non-fatal MI, non-fatal stroke, coronary revascularization, or unstable angina) in statin-treated patients with high triglycerides at elevated cardiovascular risk with high-dose EPA compared to placebo.","journal-title":"N Engl J Med"},{"key":"919_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","volume":"85","author":"V Manninen","year":"1992","unstructured":"Manninen V, Tenkanen L, Koskinen P, Huttunen JK, M\u00e4ntt\u00e4ri M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study Implications for treatment. Circulation. 1992;85:37\u201345.","journal-title":"Circulation"},{"key":"919_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/CIRCULATIONAHA.108.777334","volume":"118","author":"S Mora","year":"2008","unstructured":"Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation Lippincott Williams & Wilkins. 2008;118:993\u20131001.","journal-title":"Circulation"},{"issue":"39","key":"919_CR15","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058.","journal-title":"Eur Heart J"},{"key":"919_CR16","unstructured":"\u2022 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation. Lippincott Williams & Wilkins Hagerstown, MD; 2019. pp. e1046\u201381. Most recent North American guidelines on the management of blood cholesterol."},{"key":"919_CR17","doi-asserted-by":"crossref","unstructured":"\u2022 Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. Lippincott Williams & Wilkins Hagerstown, MD; 2011. pp. 2292\u2013333. Most comprehensive North American statement on triglycerides and cardiovascular disease.","DOI":"10.1161\/CIR.0b013e3182160726"},{"key":"919_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/1573403X14666180123165542","volume":"14","author":"K Rygiel","year":"2018","unstructured":"Rygiel K. Hypertriglyceridemia - common causes, prevention and treatment strategies. Curr Cardiol Rev. 2018;14:67\u201376.","journal-title":"Curr Cardiol Rev"},{"key":"919_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"\u2022\u2022 Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388 Most recent European guidelines on the management of dyslipidemias which integrated Omega-3 as a recommended therapy for mild-moderate hypertriglyceridemia in high-risk statin-treated patients.","journal-title":"Eur Heart J"},{"key":"919_CR20","first-page":"1483","volume":"347","author":"WE Kraus","year":"2002","unstructured":"Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N. Engl. J. Med. Massachusetts Med Soc. 2002;347:1483\u201392.","journal-title":"Massachusetts Med Soc"},{"key":"919_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ahj.2012.04.014","volume":"164","author":"KM Huffman","year":"2012","unstructured":"Huffman KM, Hawk VH, Henes ST, Ocampo CI, Orenduff MC, Slentz CA, et al. Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I. Am Heart J. 2012;164:117\u201324.","journal-title":"Am Heart J"},{"key":"919_CR22","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375:1875\u201384.","journal-title":"Lancet."},{"key":"919_CR23","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","volume":"384","author":"BG Nordestgaard","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626\u201335.","journal-title":"Lancet."},{"key":"919_CR24","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijcard.2015.04.228","volume":"191","author":"C-K Ip","year":"2015","unstructured":"Ip C-K, Jin D-M, Gao J-J, Meng Z, Meng J, Tan Z, et al. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials. Int J Cardiol. 2015;191:138\u201348.","journal-title":"Int J Cardiol"},{"key":"919_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","volume":"57","author":"E Bruckert","year":"2011","unstructured":"Bruckert E, Labreuche J, Deplanque D, Touboul P-J, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2011;57:267\u201372.","journal-title":"J Cardiovasc Pharmacol"},{"key":"919_CR26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","volume":"217","author":"M Lee","year":"2011","unstructured":"Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217:492\u20138.","journal-title":"Atherosclerosis."},{"key":"919_CR27","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3390\/ijms21041362","volume":"21","author":"JK Innes","year":"2020","unstructured":"Innes JK, Calder PC. Marine Omega-3 (N-3) fatty acids for cardiovascular health: an update for 2020. Int J Mol Sci. Multidisciplinary Digital Publishing Institute. 2020;21:1362.","journal-title":"Int J Mol Sci"},{"key":"919_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1017\/S1368980011002254","volume":"15","author":"J Zheng","year":"2012","unstructured":"Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr. Cambridge University Press. 2012;15:725\u201337.","journal-title":"Public Health Nutr"},{"key":"919_CR29","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","volume":"372","author":"L Tavazzi","year":"2008","unstructured":"Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223\u201330.","journal-title":"Lancet."},{"key":"919_CR30","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/HJR.0b013e328339cc70","volume":"17","author":"G Einvik","year":"2010","unstructured":"Einvik G, Klemsdal TO, Sandvik L, Hjerkinn EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur J Cardiovasc Prev Rehabil. SAGE PublicationsSage UK: London, England. 2010;17:588\u201392.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"919_CR31","first-page":"2015","volume":"363","author":"D Kromhout","year":"2010","unstructured":"Kromhout D, Giltay EJ, Geleijnse JM. Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. Massachusetts Med Soc. 2010;363:2015\u201326.","journal-title":"Massachusetts Med Soc"},{"key":"919_CR32","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","volume":"122","author":"B Rauch","year":"2010","unstructured":"Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. Lippincott Williams & Wilkins Hagerstown, MD. 2010;122:2152\u20139.","journal-title":"Circulation"},{"key":"919_CR33","doi-asserted-by":"publisher","first-page":"c6273","DOI":"10.1136\/bmj.c6273","volume":"341","author":"P Galan","year":"2010","unstructured":"Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ British Med J Publishing Group. 2010;341:c6273.","journal-title":"BMJ British Med J"},{"key":"919_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"J Bosch","year":"2012","unstructured":"ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. Massachusetts Medical Society. 2012;367:309\u201318.","journal-title":"N Engl J Med"},{"key":"919_CR35","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","volume":"368","author":"MC Roncaglioni","year":"2013","unstructured":"Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. Massachusetts Medical Society. 2013;368:1800\u20138.","journal-title":"N Engl J Med"},{"key":"919_CR36","first-page":"763","volume":"174","author":"DE Bonds","year":"2014","unstructured":"Writing Group for the AREDS2 Research Group, Bonds DE, Harrington M, Worrall BB, Bertoni AG, Eaton CB, et al. Effect of long-chain \u03c9-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. Intern Med American Medical Association. 2014;174:763\u201371.","journal-title":"JAMA"},{"key":"919_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","volume":"354","author":"GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)","year":"1999","unstructured":"GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447\u201355.","journal-title":"Lancet"},{"key":"919_CR38","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090\u20138.","journal-title":"Lancet."},{"key":"919_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ijcard.2016.11.105","volume":"228","author":"K Nosaka","year":"2017","unstructured":"Nosaka K, Miyoshi T, Iwamoto M, Kajiya M, Okawa K, Tsukuda S, et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study. Int J Cardiol. 2017;228:173\u20139.","journal-title":"Int J Cardiol"},{"key":"919_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","volume":"3","author":"T Aung","year":"2018","unstructured":"Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of Omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol American Medical Association. 2018;3:225\u201334.","journal-title":"JAMA Cardiol"},{"key":"919_CR41","unstructured":"\u2022\u2022 ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. N. Engl. J. Med. Massachusetts Medical Society; 2018;NEJMoa1804989. Omega-3 trial using low-dose combination of DHA\/EPA which failed to demonstrate benefit in CVD risk reduction in primary prevention."},{"key":"919_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","volume":"380","author":"JE Manson","year":"2019","unstructured":"\u2022\u2022 Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380:23\u201332 Massachusetts Medical Society. Omega-3 trial using low-dose combination of DHA\/EPA which failed to demonstrate benefit in CVD risk reduction in primary prevention.","journal-title":"N Engl J Med"},{"key":"919_CR43","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","volume":"73","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73:2791\u2013802.","journal-title":"J Am Coll Cardiol"},{"key":"919_CR44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","volume":"141","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg PG, Ketchum SB, et al. REDUCE-IT USA: results from the 3146 patients randomized in the United States. Circulation. Lippincott Williams & Wilkins Hagerstown, MD. 2020;141:367\u201375.","journal-title":"Circulation"},{"key":"919_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2014.02.025","volume":"234","author":"R Nishio","year":"2014","unstructured":"Nishio R, Shinke T, Otake H, Nakagawa M, Nagoshi R, Inoue T, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis. 2014;234:114\u20139.","journal-title":"Atherosclerosis."},{"key":"919_CR46","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1253\/circj.CJ-15-0813","volume":"80","author":"T Niki","year":"2016","unstructured":"Niki T, Wakatsuki T, Yamaguchi K, Taketani Y, Oeduka H, Kusunose K, et al. Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound. Circ J. The Japanese Circulation Society. 2016;80:450\u201360.","journal-title":"Circ J"},{"key":"919_CR47","first-page":"3131","volume":"2016","author":"RP Mason","year":"1858","unstructured":"Mason RP, Jacob RF, Shrivastava S, Sherratt SCR, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 1858;2016:3131\u201340.","journal-title":"Biochim Biophys Acta"},{"key":"919_CR48","unstructured":"Bhatt D EPA levels and cardiovascular outcomes in the reduction of cardiovascular events with icosapent ethyl\u2013intervention trial. J Am Coll Cardiol. 2020;1\u201341."},{"key":"919_CR49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jacl.2011.10.018","volume":"6","author":"TA Jacobson","year":"2012","unstructured":"Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol. 2012;6:5\u201318.","journal-title":"J Clin Lipidol"},{"key":"919_CR50","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/clc.23055","volume":"41","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41:1281\u20138.","journal-title":"Clin Cardiol"},{"key":"919_CR51","doi-asserted-by":"publisher","first-page":"e013543","DOI":"10.1161\/JAHA.119.013543","volume":"8","author":"Y Hu","year":"2019","unstructured":"\u2022 Hu Y, Hu FB, Manson JE. Marine Omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants. J Am Heart Assoc. 2019;8:e013543 Most recent meta-analysis on Omega-3 supplementation for CVD reduction demonstrating that Omega-3 supplementation lowers risk for myocardial infarction, CHD death, total CHD, CVD death, and total CVD, even after exclusion of REDUCE-IT.","journal-title":"J Am Heart Assoc"},{"key":"919_CR52","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","volume":"13","author":"CE Orringer","year":"2019","unstructured":"\u2022\u2022 Orringer CE, Jacobson TA, Maki KC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13:860\u201372 Most recent National Lipid Association guidelines on the management of dyslipidemias which integrated Omega-3 as a recommended therapy for mild-moderate hypertriglyceridemia in high-risk statin-treated patients.","journal-title":"J Clin Lipidol"},{"key":"919_CR53","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"\u2022 American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103\u201323 American Diabetes Association. Most recent American Diabetes Association guidelines on the management of dyslipidemias which integrated Omega-3 as a recommended therapy for mild-moderate hypertriglyceridemia in high-risk statin-treated patients.","journal-title":"Diabetes Care"},{"key":"919_CR54","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","volume":"140","author":"AC Skulas-Ray","year":"2019","unstructured":"Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 1st ed. Lippincott Williams & Wilkins Hagerstown, MD. 2019;140:e673\u201391.","journal-title":"Circulation"},{"key":"919_CR55","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jacc.2019.01.016","volume":"73","author":"F Picard","year":"2019","unstructured":"Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, et al. Generalizability of the REDUCE-IT trial in patients with stable coronary artery disease. J Am Coll Cardiol. 2019;73:1362\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"919_CR56","doi-asserted-by":"crossref","unstructured":"Mortensen MB, Blaha MJ, Nordestgaard BG. Eligibility and preventive potential for new evidence-based cardiovascular drugs in secondary prevention. JAMA Cardiol. 2020.","DOI":"10.1001\/jamacardio.2019.4759"},{"key":"919_CR57","first-page":"204748731989664","volume":"120","author":"Z Ademi","year":"2020","unstructured":"Ademi Z, Ofori-Asenso R, Zomer E, Owen A, Liew D. The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction. Eur J Prev Cardiol. 2020;120:2047487319896648.","journal-title":"Eur J Prev Cardiol"},{"key":"919_CR58","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0735-1097(20)32541-9","volume":"75","author":"WS Weintraub","year":"2020","unstructured":"Weintraub WS, Bhatt D, Zhang Z, Zhang C, Sarahfaye D, Boden WE, et al. Cost-effectiveness of icosapent ethyl in us reduce-it patients. J Am Coll Cardiol. 2020;75:1914.","journal-title":"J Am Coll Cardiol"},{"key":"919_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plefa.2018.01.001","volume":"129","author":"C-H Chang","year":"2018","unstructured":"Chang C-H, Tseng P-T, Chen N-Y, Lin P-C, Lin P-Y, Chang JP-C, et al. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fat Acids. 2018;129:1\u201312.","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"key":"919_CR60","first-page":"826","volume":"40","author":"MK Ito","year":"2015","unstructured":"Ito MK. A comparative overview of prescription Omega-3 fatty acid products. P T. 2015;40:826\u201357.","journal-title":"P T"},{"key":"919_CR61","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/0006-2952(96)00473-X","volume":"52","author":"HJ Kr\u00e4mer","year":"1996","unstructured":"Kr\u00e4mer HJ, Stevens J, Grimminger F, Seeger W. Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol. 1996;52:1211\u20137.","journal-title":"Biochem Pharmacol"},{"key":"919_CR62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1471-2318-14-74","volume":"14","author":"K Laake","year":"2014","unstructured":"Laake K, Myhre P, Nordby LM, Seljeflot I, Abdelnoor M, Smith P, et al. Effects of \u03c93 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study. BMC Geriatr BioMed Central. 2014;14:74\u20136.","journal-title":"BMC Geriatr BioMed Central"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-021-00919-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-021-00919-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-021-00919-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T03:06:07Z","timestamp":1675134367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-021-00919-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1007\/s11883-021-00919-2","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"9 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Dr. Picard reports personal fees from Biotronik, grants from BBraun, personal fees from BMS, and personal fees from Sanofi, outside the submitted work. Dr. Steg reports grants and personal fees from Amarin, during the conduct of the study; personal fees from Amgen; personal fees from AstraZeneca; personal fees from BMS; personal fees from Boehringer Ingelheim; personal fees from Idorsia; personal fees from Pfizer; personal fees from Novartis; grants, personal fees, and non-financial support from Sanofi\/Regeneron; grants and personal fees from Servier; grants and personal fees from Bayer, outside the submitted work; in addition, Dr. Steg has a patent use of alirocumab to reduce risk after ACS (royalties to Sanofi) issued.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"27"}}